Lenalidomide (LEN) is an immunomodulatory compound with significant activity versus relapsed/refractory multiple myeloma (RRMM).[1][1] In Blood , Rajkumar et al[2][2] reported striking efficacy of LEN plus dexamethasone (DEX) versus newly diagnosed multiple myeloma (NDMM). While structurally similar
No takes yet. Share an insight, caveat, or question.
Zonder et al. (2006) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: